Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Net Income Loss of -$38.55 million for the year ending 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -152.2% in Net Income Loss from 2024 to 2025.
- This data is from SUPERNUS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), SUPERNUS PHARMACEUTICALS, INC.'s Net Income Loss has declined by 0.2%.
- Historical annual values: Fiscal year 2025: -$38.55 million | Fiscal year 2024: $73.87 million | Fiscal year 2023: $1.32 million | Fiscal year 2022: $60.71 million | Fiscal year 2021: $53.42 million | Fiscal year 2020: $126.95 million | Fiscal year 2019: $113.06 million | Fiscal year 2018: $110.99 million | Fiscal year 2017: $57.28 million | Fiscal year 2016: $91.22 million | Fiscal year 2015: $13.94 million | Fiscal year 2014: -$10.93 million | Fiscal year 2013: -$92.27 million | Fiscal year 2012: -$46.28 million | Fiscal year 2011: $53.82 million | Fiscal year 2010: -$38.46 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: